1. Revenue Performance: Q3 2024 revenue reached $99.22 billion, up 9% YoY. Revenue growth was driven by robust performances across segments, particularly in OptumHealth and OptumRx, which grew by $2 billion and $5 billion, respectively.
2. Profitability Metrics: The gross profit margin slightly decreased to 21.6% from 22.5% YoY due to rising operational costs stemming from higher acuity patients and regulatory changes. Net income was $6.06 billion, with a net profit margin of 6.1%. EPS increased by 3.96% YoY, showcasing operational resilience despite cost pressures.
3. Cash Flow and Balance Sheet: Operating cash flow for Q3 was $14 billion, with free cash flow at about $12.95 billion, reflecting strong cash-generating capabilities. The ending cash position improved to $32.4 billion compared to $26.3 billion at the beginning of the quarter. Total debt to total capitalization stood at 43.9%, indicating a manageable debt load in line with industry standards.